novoPT™ technology
Biotica's novoPT™ (novel optimised Polyketide Therapeutics) technology generates unique, differentiated polyketide therapeutics.
Polyketides: rich source of pharmaceuticals
Polyketides are a well recognised and documented class of compounds that have historically generated more than 40 approved pharmaceuticals in a wide range of settings. There are a further 5-10,000 known polyketides, providing Biotica with a largely untapped resource of drug discovery leads. More…
Benefits of polyketides as drug leads
Polyketides are great starting points for drug discovery. They often have naturally high target affinity for biologically relevant targets and can sometimes address traditionally difficult targets, such as protein-protein interactions. More…
novoPT™: a unique approach to drug discovery
In a novoPT™ programme, Biotica genetically alters a polyketide-producing micro-organism so that it produces a new polyketide compound. novoPT™ accesses novel chemical space compared to conventional medicinal chemistry techniques, so novoPT™ compounds are patentable NCEs as well as being biologically differentiated. Combining different alterations creates a targeted library of analogues, from which Biotica selects a drug candidate. More…
Find out more
Click on the links for more about:
Benefits of polyketides as drug leads
Optimisation using novoPT™
Links to papers describing the technology and its applications
